Pediatric Primary Pulmonary Hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Primary pulmonary hypertension (PPH) is a progressive, life-limiting disease.
• Current therapeutic options for PPH are palliative, not curative, and carry significant side effects.
• Despite limitations, available therapies are crucial for improving patient quality of life and survival.

Purpose of the Study:

• To outline a hierarchical approach to managing primary pulmonary hypertension.
• To guide clinicians in selecting optimal therapeutic regimens based on disease progression.
• To emphasize the importance of palliative care and judicious use of advanced therapies.

Main Methods:

• Review of current literature on primary pulmonary hypertension management.
• Development of a tiered therapeutic strategy based on efficacy and morbidity.
• Inclusion of established and emerging treatment modalities.

Main Results:

• A recommended hierarchy of therapy for PPH is presented, starting with supportive care and progressing to advanced interventions.
• The hierarchy includes anticongestive therapy, anticoagulation, oxygen, calcium channel blockers, prostacyclin, beta-agonists, and lung transplantation.
• Organ replacement is reserved for end-stage disease after failure of all other treatments.

Conclusions:

• Effective management of PPH requires a tailored, stepwise therapeutic approach.
• Palliative therapies significantly improve quality of life and prolong survival in PPH patients.
• Emerging therapies are expected to further refine PPH treatment strategies in the future.